259 related articles for article (PubMed ID: 26301456)
21. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
22. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
23. Metoprolol improves survival in severe traumatic brain injury independent of heart rate control.
Zangbar B; Khalil M; Rhee P; Joseph B; Kulvatunyou N; Tang A; Friese RS; O'Keeffe T
J Surg Res; 2016 Feb; 200(2):586-92. PubMed ID: 26365164
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
25. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
26. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
27. β-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer.
Sakellakis M; Kostaki A; Starakis I; Koutras A
Chemotherapy; 2014; 60(5-6):288-9. PubMed ID: 25998892
[TBL] [Abstract][Full Text] [Related]
28. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients.
Udumyan R; Montgomery S; Duberg AS; Fang F; Valdimarsdottir U; Ekbom A; Smedby KE; Fall K
Scand J Gastroenterol; 2020 May; 55(5):597-605. PubMed ID: 32412855
[No Abstract] [Full Text] [Related]
29. Beta-blockers and depression in elderly hypertension patients in primary care.
Ringoir L; Pedersen SS; Widdershoven JW; Pouwer F; Keyzer JM; Romeijnders AC; Pop VJ
Fam Med; 2014 Jun; 46(6):447-53. PubMed ID: 24911300
[TBL] [Abstract][Full Text] [Related]
30. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
31. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
Peiretti M; Zanagnolo V; Aletti GD; Bocciolone L; Colombo N; Landoni F; Minig L; Biffi R; Radice D; Maggioni A
Gynecol Oncol; 2010 Nov; 119(2):259-64. PubMed ID: 20800269
[TBL] [Abstract][Full Text] [Related]
32. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
33. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of beta-blockers in women with congestive heart failure.
Keyhan G; Chen SF; Pilote L
J Gen Intern Med; 2007 Jul; 22(7):955-61. PubMed ID: 17468890
[TBL] [Abstract][Full Text] [Related]
35. Comparison of in-hospital outcomes for beta-blocker use versus non-beta blocker use in patients presenting with cocaine-associated chest pain.
Fanari Z; Kennedy KK; Lim MJ; Laddu AA; Stolker JM
Am J Cardiol; 2014 Jun; 113(11):1802-6. PubMed ID: 24742472
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
37. Lack of physician concordance with guidelines on the perioperative use of beta-blockers.
Siddiqui AK; Ahmed S; Delbeau H; Conner D; Mattana J
Arch Intern Med; 2004 Mar; 164(6):664-7. PubMed ID: 15037496
[TBL] [Abstract][Full Text] [Related]
38. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis.
TenBrook JA; Wolf MP; Hoffman SN; Rosenwasser LJ; Konstam MA; Salem DN; Wong JB
J Allergy Clin Immunol; 2004 May; 113(5):977-82. PubMed ID: 15131583
[TBL] [Abstract][Full Text] [Related]
39. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
Minlikeeva AN; Freudenheim JL; Cannioto RA; Szender JB; Eng KH; Modugno F; Ness RB; LaMonte MJ; Friel G; Segal BH; Odunsi K; Mayor P; Zsiros E; Schmalfeldt B; Klapdor R; Dӧrk T; Hillemanns P; Kelemen LE; Kӧbel M; Steed H; de Fazio A; ; Jordan SJ; Nagle CM; Risch HA; Rossing MA; Doherty JA; Goodman MT; Edwards R; Matsuo K; Mizuno M; Karlan BY; Kjær SK; Høgdall E; Jensen A; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LF; Kupryjanczyk J; Berchuck A; Chang-Claude J; Diergaarde B; Webb PM; Moysich KB;
Cancer Causes Control; 2017 May; 28(5):469-486. PubMed ID: 28293802
[TBL] [Abstract][Full Text] [Related]
40. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
